 |
Phase 3 MARINE Trial Data to be Presented in May at the National Lipid Association 2011 Annual Scientific Sessions
5 Apr 2011
|
62.7 KB |
|
| |
MYSTIC, Conn. and DUBLIN, April 5, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that data from the MARINE trial, a pivotal Phase 3 study investigating AMR101 as a treatment for very high triglycerides (≥500 mg/dL), will be present...
|
|
Amarin to Present at the 10th Annual Needham Healthcare Conference
31 Mar 2011
|
10.3 KB |
|
| |
MYSTIC, Conn. and DUBLIN, March 31, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Executive Chairman and Chief Executive Officer, Joseph Zakrzewski, will present at 8:40 a.m. EDT on April, 6, 2011 at the 10th Annual Needham Healthca...
|
|
Amarin Reports Year-End and Q4 2010 Results
16 Mar 2011
|
|
| |
DUBLIN and MYSTIC, Conn., March 16, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company focused on cardiovascular disease, today reported financial results for the fiscal year and fourth quarter ended December 31, 2010. The Company also provided an update on its progress with the Phase 3 developmen...
|
|
Amarin to Present at Two Upcoming Investor Conferences
8 Mar 2011
|
58.5 KB |
|
| |
MYSTIC, Conn. and DUBLIN, March 8, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that it is scheduled to participate in two upcoming investor conferences: the Barclays Capital 2011 Global Healthcare Conference on Tuesday, March 15, 2011 and the ROTH 23rd Annual OC Growth Stock Conference on Wednesday, March 16, 2011.
...
|
|
Amarin to Present at Two Upcoming Investor Conferences
22 Feb 2011
|
58.0 KB |
|
| |
MYSTIC, Conn. and DUBLIN, Feb 22, 2011 Amarin Corporation plc (Nasdaq: AMRN) today announced that members of its senior management team will be presenting at two investor conferences on March 2, 2011.
Joseph Zakrzewski, Executive Chairman and Chief Executive Officer, is scheduled to present at the CITI 2011 Global Healthcare Conference on Wednes...
|
|
Amarin to Present at the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
7 Feb 2011
|
58.0 KB |
|
| |
MYSTIC, Conn. and DUBLIN, Feb. 7, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that it is scheduled to participate in the Leerink Swann Hot Topics in Therapeutics Roundtable Conference on Wednesday, February 16, 2011. Amarin's participation includes both a panel discussion on Cardiology at 7:45am ET and a company prese...
|
|
Amarin Corporation Appoints Industry Veteran Paul E. Huff as Chief Commercial Officer
2 Feb 2011
|
62.8 KB |
|
| |
DUBLIN and MYSTIC, Conn., Feb. 2, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Paul E. Huff has joined the Company as Chief Commercial Officer. In this role, Mr. Huff is responsible for driving Amarin's AMR101 commercialization str...
|
|
Amarin Provides 2010 Year-End Review to Shareholders
31 Jan 2011
|
67.2 KB |
|
| |
DUBLIN and MYSTIC, Conn., Jan. 31, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today issued a special letter to its shareholders. The text of the letter, written by Joseph S. Zakrzewski, Executive Chairman and Chief Executive Officer of Amarin, follow...
|
|
Amarin Announces Successful Completion of Offering of American Depositary Shares
11 Jan 2011
|
60.1 KB |
|
| |
MYSTIC, Conn. and DUBLIN, Jan. 11, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN) (the "Company"), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that it has completed its previously announced underwritten public offering of American Depositary Shares ("ADSs") at a price to the public ...
|
|
Amarin Announces Underwriters' Exercise of Over-Allotment Option
7 Jan 2011
|
62.4 KB |
|
| |
MYSTIC, Conn. and DUBLIN, Jan. 7, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN) (the "Company"), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that, in connection with its previously announced underwritten public offering of American Depositary Shares ("ADSs"), the underwriters of th...
|
|
Amarin Prices Public Offering of American Depositary Shares
6 Jan 2011
|
60.1 KB |
|
| |
MYSTIC, Conn. and DUBLIN, Jan. 6, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN) (the "Company"), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced the pricing of an underwritten public offering of 12,000,000 American Depositary Shares ("ADSs") at a price to the public of $7.60 per ADS. T...
|
|
Amarin Announces Proposed Public Offering of American Depositary Shares
5 Jan 2011
|
59.7 KB |
|
| |
MYSTIC, Conn. and DUBLIN, Jan. 5, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN) (the "Company"), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that it intends to offer for sale its American Depositary Shares in an underwritten public offering. Jefferies & Company, Inc. and Leerink Sw...
|
|
Amarin to Present at the 29th Annual J.P. Morgan Healthcare Conference
5 Jan 2011
|
57.2 KB |
|
| |
MYSTIC, Conn. and DUBLIN, Jan. 5, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that it is scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2011 at 1:00pm PST. The conference will be held at the Westin St. Francis Hotel in San Francisco.
A live audio webcast of the pr...
|
|
Amarin Completes Patient Randomization in Phase 3 ANCHOR Trial
16 Dec 2010
|
60.6 KB |
|
| |
MYSTIC, Conn., and DUBLIN, Dec. 16, 2010 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported the completion of patient randomization for its ANCHOR trial, a pivotal Phase 3 trial of AMR101. The Company indicated that it anticipates reporti...
|
|
Amarin to Present at Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference
3 Dec 2010
|
57.1 KB |
|
| |
MYSTIC, Conn. and DUBLIN, Dec. 3, 2010 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that it is scheduled to present at the Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference on Tuesday, December 7, 2010 at 3:00pm PST. The conference will be held at the Nikko Hotel in San Francisco.
A liv...
|
|
Amarin's AMR101 Meets Pivotal Phase 3 Study Endpoints With Highly Statistically Significant Reductions in Triglycerides at 4 Gram and 2 Gram Doses in MARINE Trial With No Statistically Significant Increase in LDL-C and Safety Profile Similar to Placebo
29 Nov 2010
|
69.0 KB |
|
| |
MYSTIC, Conn. and DUBLIN, Nov. 29, 2010 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from the MARINE study, its first Phase 3 clinical trial of lead drug candidate AMR101. The MAR...
|
|
Amarin to Host Conference Call at 8:30 a.m. EST on November 29, 2010, to Discuss Top-Line Results of Phase 3 MARINE Study of AMR101 in Patients with Very High Triglycerides
26 Nov 2010
|
12.6 KB |
|
| |
MYSTIC, Conn. and DUBLIN, Nov. 26, 2010 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that it will host a conference call at 8:30 a.m. EST on Monday, November 29, 2010, to discuss the top-line results from its Phase 3 MARINE trial. ...
|
|
Amarin Corporation Appoints Kristine Peterson to Board of Directors
18 Nov 2010
|
11.0 KB |
|
| |
DUBLIN and MYSTIC, Conn., Nov. 18, 2010 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced the appointment of Kristine Peterson to its board of directors.
Ms. Peterson has more than 27 years of pharmaceutical industry experience, inc...
|
|
Amarin to Present at Lazard Capital Markets Annual Healthcare Conference
15 Nov 2010
|
9.4 KB |
|
| |
DUBLIN and MYSTIC, Conn., Nov. 15, 2010 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that it is scheduled to present at the Lazard Capital Markets 7th Annual Healthcare Conference on Tuesday, November 16, 2010 at 3:10pm. Representing Amarin at this conference will be Joseph Zakrzewski, Chairman and Chief Executiv...
|
|
Amarin Reports Third Quarter 2010 Financial Results and Positively Updates Phase 3 Guidance
10 Nov 2010
|
18.0 KB |
|
| |
DUBLIN, Ireland and MYSTIC, Conn., Nov. 10, 2010 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company focused on cardiovascular disease, today reported its financial and operational results for the three-month period ended September 30, 2010. In addition, the Company provided an update regardi...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter